BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, which was a “rare” operational lapse of commercial execution amid a slowdown of orders from early August through late October, impacts from the hurricanes of as much as 18% of orders, and a slower ramp in the new sales rep hire, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target lowered to $82 from $90 at TD Cowen
- Exact Sciences price target lowered to $67 from $70 at Baird
- Exact Sciences price target lowered to $75 from $88 at BofA
- Exact Sciences price target lowered to $75 from $80 at Citi
- Exact Sciences price target lowered to $75 from $95 at Canaccord